Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience

BACKGROUND: Vandetanib is the most widely used tyrosine kinase inhibitor for the treatment of patients with advanced medullary thyroid cancer (MTC). However, only limited data regarding its use outside clinical trials are available. We aimed to evaluate the efficacy and safety of vandetanib in patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Endocrinol Metab (Seoul)
Asıl Yazarlar: Kim, Mijin, Yoon, Jee Hee, Ahn, Jonghwa, Jeon, Min Ji, Kim, Hee Kyung, Lim, Dong Jun, Kang, Ho-Cheol, Kim, In Joo, Shong, Young Kee, Kim, Tae Yong, Kim, Bo Hyun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Korean Endocrine Society 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7520595/
https://ncbi.nlm.nih.gov/pubmed/32981301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2020.687
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller